Cargando…
MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by obstructed pulmonary vasculatures. Current therapies for PAH are limited and only alleviate symptoms. Reduced levels of BMPR2 are associated with PAH pathophysiology. Moreover, reactive oxygen species, inflammation...
Autores principales: | Gomez-Puerto, Maria Catalina, Sun, Xiao-Qing, Schalij, Ingrid, Orriols, Mar, Pan, Xiaoke, Szulcek, Robert, Goumans, Marie-José, Bogaard, Harm-Jan, Zhou, Qian, ten Dijke, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312610/ https://www.ncbi.nlm.nih.gov/pubmed/32531895 http://dx.doi.org/10.3390/ijms21114130 |
Ejemplares similares
-
Impact of MnTBAP and Baricitinib Treatment on Hutchinson–Gilford Progeria Fibroblasts
por: Vehns, Elena, et al.
Publicado: (2022) -
MnTBAP Therapy Attenuates Renal Fibrosis in Mice with 5/6 Nephrectomy
por: Yu, Jing, et al.
Publicado: (2016) -
MnTBAP therapy attenuates the downregulation of sodium transporters in obstructive kidney disease
por: Liu, Mi, et al.
Publicado: (2017) -
Temporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer
por: Da Rocha, Sylvie, et al.
Publicado: (2019) -
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension
por: Orriols, Mar, et al.
Publicado: (2017)